Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3173765 | 0.99 | KMT2A (0.44) | KMT2AFABP5FABP7L3MBTL1EPHX2 | |
| SCHEMBL11902048 | 0.94 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL2039581 | 0.90 | KMT2A (0.42) | KMT2AFABP5FABP7L3MBTL1EPHX2 | |
| SCHEMBL6651104 | 0.88 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL6796558 | 0.85 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL11964044 | 0.83 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL377928 | 0.81 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL25797253 | 0.81 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2OPRD1 | |
| SCHEMBL15181329 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7L3MBTL1EPHX2 | |
| SCHEMBL8933069 | 0.81 | FABP5 (0.42) | KMT2AFABP5FABP7EPHX2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250362310-A1 | STRUCTURE-BASED PROBE FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | SCHERING CORPORATION | 2002-02-07 | — | — | US | disclosed |
| WO-2001081325-A2 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING ALKYL AND ARYL ALANINE P2 MOIETIES | SCHERING CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-6018020-A | VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G | HOFFMAN-LA ROCHE INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | KMT2A 4305/4885FABP5 2597/4885FABP7 1036/4885 |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | KMT2A 1306/4885FABP5 1749/4885FABP7 747/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | KMT2A 1528/4885FABP5 1949/4885FABP7 2027/4885 |
| US-20020016294-A1 | Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties | PRSS3, HPN, DPP3 | KMT2A 3306/4885FABP5 2599/4885FABP7 3326/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | KMT2A 2286/4885FABP5 1547/4885FABP7 1488/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | KMT2A 4343/4885FABP5 652/4885FABP7 520/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | KMT2A 2286/4885FABP5 1547/4885FABP7 1488/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | KMT2A 4310/4885FABP5 2640/4885FABP7 1056/4885 |
| US-20260036595-A1 | STRUCTURE-BASED PEPTIDES FOR DETECTION OF TRANSTHYRETIN AMYLOID FIBRILS AND AGGREGATES IN PREECLAMPSIA | TTR, APP, SERPINA3 | KMT2A 4282/4885FABP5 115/4885FABP7 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.